Compare
Entrada Therapeutics, Inc. vs Celularity Inc vs Alumis Inc. vs Cue Biopharma, Inc.
| Latest fiscal year | Entrada Therapeutics, Inc. TRDA | Celularity Inc CELU | Alumis Inc. ALMS | Cue Biopharma, Inc. CUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $25.42M | $26.55M | $24.05M | $27.47M |
| Revenue growth (YoY) | -87.9% | -51.0% | n/a | +195.7% |
| Gross margin | n/a | 24.4% (computed) | n/a | n/a |
| Operating margin | -621.1% | -230.9% | n/m | -96.7% |
| Net margin | -565.5% | -345.4% | n/m | -96.9% |
| Net income | -$143.75M | -$91.72M | -$243.32M | -$26.60M |
| EPS (Diluted) | -$3.47 | -$3.59 | -$2.86 | -$0.28 |
| Operating cash flow | -$128.51M | -$13.25M | -$369.52M | -$21.69M |
| Free cash flow | -$129.55M | n/a | -$370.18M | -$21.86M |
| Cash & equivalents | $90.39M | $6.17M | $89.67M | $27.14M |
| Total assets | $377.38M | $107.33M | $411.94M | $42.21M |
| Total liabilities | $71.25M | $145.39M | $110.64M | $15.78M |
| Shareholders' equity | $306.13M | -$38.06M | $301.30M | $26.43M |
| Return on year-end equity | -47.0% | n/a | -80.8% | -100.6% |
| Shares outstanding | 38.28M | 28.84M | n/a | 96.62M |
Revenue, most recent five fiscal years
| Fiscal year | Entrada Therapeutics, Inc. | Celularity Inc | Alumis Inc. | Cue Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $25.42M Ended 2025-12-31 | $26.55M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $27.47M Ended 2025-12-31 |
| 1 year earlier | $210.78M Ended 2024-12-31 | $54.22M Ended 2024-12-31 | n/a | $9.29M Ended 2024-12-31 |
| 2 years earlier | $129.01M Ended 2023-12-31 | $22.77M Ended 2023-12-31 | n/a | $5.49M Ended 2023-12-31 |
| 3 years earlier | n/a | $17.98M Ended 2022-12-31 | n/a | $1.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $21.34M Ended 2021-12-31 | n/a | $14.94M Ended 2021-12-31 |